Billing

ICD-10

As of October 1, 2015, ICD-10-CM diagnosis codes replaced the previous ICD-9-CM diagnosis codes in all health care settings for diagnosis reporting. ICD-9 codes are no longer accepted or provided evidence of medical necessity for ordered laboratory services.

Please see our summary of changes that specifically pertain to the diagnosis codes that may indicate ThyGenX® and ThyraMIR™.

ThyGenX is covered under local Medicare policy L35396. You can reference this policy on the CMS website at: http://go.cms.gov/1iePqm5. Also available on the CMS website is additional information for providers regarding ICD-10: www.cms.hhs.gov/icd10. Diagnosis codes submitted with test orders should always be based on what can be supported within the patient’s medical record.

Financial Options

At Interpace Diagnostics, we are committed to providing patients with access to personalized medicine, regardless of their personal financial situation.

Since coverage differs by insurance plan, Interpace Diagnostics has implemented the COMPASS* Program, which offers needs-based financial assistance and payment plans. All tests provided by Interpace Diagnostics are covered in the COMPASS Program.

Financial Assistance

Interpace Diagnostics tailors financial assistance solutions for patients, accounting for factors such as income and family unit size. Tiered discounts are based on guidelines provided by the US Department of Health and Human Services and can be as much as 100% of your amount due. All patients are encouraged to apply.

Payment Plans

Interest free payment plans are available to all patients unable to pay their full balance by the due date.

*COMPASS is not available to patients covered by Medicare, Medicaid, or any other government program, or where the program is restricted or prohibited by contractual obligation, or federal or state law. COMPASS is only available to patients within the United States.

Questions?

If you have any questions about the program or eligibility, please call 866.445.6719.
Next

Limitations and Disclaimers:

The ThyraMIR™ microRNA Classifier and the ThyGenX® Oncogene Panel each consist of markers strongly associated with thyroid cancer and whose detection in preoperative thyroid nodule aspirations have been shown to be highly predictive for thyroid cancer. These tests are intended to aid in the diagnosis of thyroid nodules with indeterminate cytology; positive or negative test results should be interpreted in conjunction with all other available clinical data. These tests were developed and performance characteristics determined by Interpace Diagnostics. They have not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing used for clinical purposes. These tests are used for clinical purposes. Tests should not be regarded as investigational or for research. Final diagnosis and optimal patient management are the responsibility of the referring physician or health care provider.

References:

  1. Labourier E, Beaudenon A, Wylie D, Giordano TJ. Multi-categorical testing for miRNA, mRNA and DNA on fine needle aspiration improves the preoperative diagnosis of thyroid nodules with indeterminate cytology. ENDO 2015. Presented at the 97th Meeting and Expo of the Endocrine Society March 5-8, 2015. SAT-344.
  2. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer statistics review 1975-2011. Section 26. thyroid. http://seer.cancer.gov/csr/1975_2011/
    results_merged/sect_26_thyroid.pdf. Accessed October 1, 2015.
  3. Beaudenon-Huibregtse S, Alexander EK, Guttler RB, et al. Centralized molecular testing for oncogenic gene mutations complements the local cytopathological diagnosis of thyroid nodules. Thyroid. 2014;24(10):1479-1487.
  4. Ferraz C, Eszlinger M, Paschke R. Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules. J Clin Endocrinol Metab. 2011;96(7): 2016-2206.
  5. Data on File Packet 0001. Interpace Diagnostics. Parsippany, NJ.
  6. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-214.
  7. Nikiforov YE, Nikiforova MN. Molecular genetics and the diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7(10):569-580.
  8. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Thyroid carcinoma Version 2.2014. Available at: www.nccn.org. Accessed October 1, 2015.
  9. Wang CC, Friedman L, Kennedy GC, et al. A large multicenter correlation study of thyroid nodule cytopathology and histopathology. Thyroid. 2011;21(3):243-251.